SPACA7: A Potential Drug Target for Neurological Disorders (G122258)

Target Name: SPACA7

NCBI ID: G122258

SPACA7

SPACA7: A Potential Drug Target for Neurological Disorders

SPACA7 (C13orf28) is a gene that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique genetic mutation has led to a gain of function in the gene, resulting in the production of a Fragile X-linked protein (FXNP) that has been linked to a range of neurological and developmental disorders.

The Fragile X-linked protein is a protein that is typically synthesized in the brain and other nervous tissue, but it can also be found in other tissues and cells, including heart, lungs, and eyes. It is known for its role in the development and progression of a variety of neurological and developmental disorders, including those that are Fragile X-linked.

SPACA7 is a gene that has been implicated in the development of several neurological and developmental disorders, including Fragile X syndrome, which is a genetic disorder that is characterized by the development of repeating unit chromosomes, mental retardation, and a range of motor and sensory symptoms . The Fragile X syndrome is typically caused by a mutation in the FX1F1 gene, which is located on the Fragile X chromosome.

SPACA7 is also associated with the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. These conditions are characterized by the progressive loss of brain cells and the development of aggregates of the protein tau, which are thought to contribute to the development and progression of these diseases.

In addition to its association with neurological and developmental disorders, SPACA7 has also been linked to the development of autoimmune disorders. Autoimmune disorders are a group of conditions that occur when the immune system mistakenly attacks healthy cells or tissues in the body. The symptoms of autoimmune disorders can vary widely, but they typically involve inflammation, pain, and fatigue.

SPACA7 is thought to contribute to the development and progression of autoimmune disorders by affecting the immune system's response to environmental stimuli. TheFXNP protein has been shown to interact with several immune system proteins, including T cells and B cells. These interactions may play a role in the development of autoimmune disorders by disrupting the balance between the immune system and the body's immune response.

In conclusion, SPACA7 is a gene that has been identified as a potential drug target and biomarker for a range of neurological and developmental disorders, including Fragile X syndrome, neurodegenerative diseases, and autoimmune disorders. Its unique genetic mutation and association with a range of disorders makes it a promising target for future research and development of new treatments.

Protein Name: Sperm Acrosome Associated 7

Functions: Involved in fertilization. Seems not to play a direct role in sperm-egg binding or gamete fusion

The "SPACA7 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SPACA7 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets